Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I^TM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases, leveraging Nona's proprietary HCAb Harbour Mice^® technology platform.

Nona's HCAb Harbour Mice^® platform enables the generation of fully human heavy-chain-only antibodies (HCAbs), offering key advantages such as reduced immunogenicity and enhanced versatility for next-generation biotherapeutics. This innovative platform has been clinically validated and widely recognized by global partners.

"We are pleased to collaborate with Visterra and support the development of their biotherapeutic pipeline," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences. "This collaboration reflects our commitment to advancing biotherapeutic innovation. By leveraging our fully human HCAbs, we aim to unlock new therapeutic possibilities and accelerate the development of transformative medicines for patients worldwide."